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Abstract
 
Recently, it has become clear that dendritic cells (DCs) are essential for the priming of T cell
responses. However, their role in the maintenance of peripheral T cell tolerance remains
largely undefined. Herein, an antigen-presenting cell (APC) transfer system was devised and
applied to experimental allergic encephalomyelitis (EAE), to evaluate the contribution that
 
DCs play in peripheral T cell tolerance. The CD8
 
 
 
 
 
CD4
 
  
 
subset, a minor population
among splenic DCs, was found to mediate both tolerance and bystander suppression against
diverse T cell specificities. Aggregated (agg) Ig-myelin oligodendrocyte glycoprotein
(MOG), an Ig chimera carrying the MOG 35–55 peptide, binds and cross-links Fc
 
 
 
R on
APC leading to efficient peptide presentation and interleukin (IL)-10 production. Further-
more, administration of agg Ig-MOG into diseased mice induces relief from clinical EAE in-
volving multiple epitopes. Such recovery could not occur in Fc
 
 
 
R-deficient mice where
both uptake of Ig-MOG and IL-10 production are compromised. However, reconstitution
of these mice with DC populations incorporating the CD8
 
 
 
 
 
CD4
 
 
 
 subset restored Ig-MOG–
mediated reversal of EAE. Transfer of CD8
 
 
 
 
 
 or even CD8
 
 
 
 
 
CD4
 
 
 
 DCs had no effect on
the disease. These findings strongly implicate DCs in peripheral tolerance and emphasize
their functional potency, as a small population of DCs was able to support effective suppression
of autoimmunity.
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Introduction
 
Dendritic cells (DCs)
 
*
 
 represent a phenotypically heteroge-
neous population endowed with an important biologic
function, namely, the presentation of antigen to both B and
T lymphocytes (1–4). To date, it is believed that priming of
naive T cells and stimulation of primary T cell responses are
mainly a function of DCs with minimal contribution from
other professional APCs (2, 3). Furthermore, recent evi-
dence has indicated that different DC subsets confer dis-
crete developmental functions to T cells (5–8). Accord-
ingly, human DC1 and mouse CD8
 
 
 
 
 
 DC subsets were
shown to promote differentiation into Th1 effectors, while
human DC2 and mouse CD8
 
 
 
  
 
subsets supported devel-
opment of Th2 cells (6–8). More recently, DCs have been
shown to internalize apoptotic bodies and necrotic debris
(9, 10) and cross-present (11) antigens exogenously ac-
quired from the dead cells by intersecting the endogenous
pathway of antigen presentation. This phenomenon has
proven quite potent in cross-priming cytolytic T lympho-
cytes (10–13) and may provide a valuable tool for thera-
peutic vaccination against tumors (14–15). Our current
knowledge on the roles that DCs play in T cell priming has
been growing steadily due to the availability of experimen-
tal models. However, little is known about the critical con-
tribution of DCs to central tolerance (16–18), and our
knowledge on their role in peripheral tolerance is still in its
infancy (19). In this report, we have devised an APC trans-
fer system that was applied to the well-characterized exper-
imental allergic encephalomyelitis (EAE) model of au-
toimmunity and evaluated the contribution of splenic DCs
to peripheral T cell tolerance.
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In prior studies, we have demonstrated that Ig-myelin
proteolipid protein (PLP)1, an Ig-chimera carrying the en-
cephalitogenic PLP1 peptide corresponding to amino acid
(aa) sequence 139–151 of proteolipid protein (PLP), is pre-
sented to T cells 100-fold better than free PLP1 (20). In
addition, aggregation of Ig-PLP1 facilitates cross-linking of
Fc
 
 
 
 receptors (Fc
 
 
 
R) on APCs and induces production of
IL-10 by both macrophages and DCs (21) without stimu-
lating upregulation of costimulatory molecules (22). Con-
sequently, aggregated (agg) Ig-PLP1 induced a dramatic
reduction in paralytic severity and promoted full recovery
from EAE when it was administered free of adjuvant into
mice with ongoing disease (21, 22). The likely mechanism
underlying the effective suppression of EAE by agg Ig-
PLP1 maybe a synergy between efficient peptide presenta-
tion, lack of costimulation, and IL-10–mediated bystander
suppression (22). In Fc
 
 
 
R-deficient (Fc
 
 
 
R
 
 
 
/
 
 
 
) mice, agg
Ig-PLP1–mediated peptide presentation and IL-10 pro-
duction by APC would be compromised. Thus, these
mutant mice offer a suitable host into which to transfer wild-
type DCs and evaluate their contribution to agg Ig-PLP1–
mediated modulation of autoreactive T cells and mainte-
nance of peripheral tolerance. However, due to the lack of
Fc
 
 
 
R
 
 
 
/
 
 
 
 mice on the SJL/J (H-2
 
s
 
) background we opted
to instead engineer the I-A
 
b
 
-restricted myelin oligoden-
drocyte glycoprotein (MOG) aa 35–55 peptide (23) into
the Ig backbone and use the resulting Ig-MOG chimera
along with Fc
 
 
 
R
 
 
 
/
 
 
 
 C57Bl/6 mice (24, 25) to evaluate
the contribution of DCs to peripheral tolerance. The re-
sults outlined in this report demonstrate that agg Ig-MOG
reverses clinical EAE induced in C57Bl/6 mice by injec-
tion of central nervous system (CNS) homogenate, as did
agg Ig-PLP1 in the SJL/J mice. This indicates that by-
stander suppression of diverse T cell specificities is also op-
erative in the Ig-MOG/C57Bl/6 system. When a similar
treatment regimen with agg Ig-MOG was applied to
Fc
 
 
 
R
 
 
 
/
 
 
 
 C57Bl/6 mice recovery from disease did not oc-
cur. This result was anticipated as both agg Ig-MOG–
driven peptide presentation and IL-10 production by
APCs would be compromised in these Fc
 
 
 
R
 
 
 
/
 
 
 
 mice.
However, transfer of wild-type C57Bl/6 DCs into the
Fc
 
 
 
R
 
 
 
/
 
 
 
 mice before treatment with agg Ig-MOG re-
stored Ig-MOG–mediated reversal of disease. To gain
further insight into how DCs operate the modulation of
autoreactive T cells, DCs were separated into subsets and
tested both for cytokine production in vitro upon incu-
bation with agg Ig chimeras and for restoration of agg
Ig-chimera reversal of EAE in the Fc
 
 
 
R
 
 
 
/
 
 
 
 mice. The
results indicated that upon cross-linking of Fc
 
 
 
R by the
Ig-chimeras the CD8
 
 
 
  
 
DCs secreted IL-10 and re-
versed EAE in the mutant mice while the CD8
 
 
 
 
 
 DCs
were unable to reverse EAE and instead produced IL-12.
More striking, further separation of the CD8
 
 
 
  
 
DCs
into CD8
 
 
 
 
 
CD4
 
 
 
 and CD8
 
 
 
 
 
CD4
 
  
 
populations in-
dicated that IL-10 production was confined to the
CD8
 
 
 
 
 
CD4
 
 
 
 subset, which also supported suppression
of autoreactive T cells and reversal of EAE in the Fc
 
 
 
R-
deficient mice.
 
Materials and Methods
 
Animals
 
sJL/J mice were purchased from Harlan-Sprague-Dawley and
C57Bl/6 mice from The Jackson Laboratory. Fcerg1 (Fc
 
 
 
RI
and III
 
 
 
/
 
 
 
), Fcgr2b (Fc
 
 
 
RII
 
 
 
/
 
 
 
), and Fcer1g/Fcgr2 (Fc
 
 
 
RI, II,
and III
 
 
 
/
 
 
 
) mice (24, 25) were purchased from Taconic. All mice
were bred and maintained in our animal care facility for the dura-
tion of the experiments. All experimental procedures were per-
formed according to the guidelines of the institutional animal care
committee.
 
Antigens
 
Peptides.
 
The peptides used in this study were purchased
from Research Genetics (Huntsville, AL) and were HPLC puri-
fied to 
 
 
 
90% purity. PLP1 peptide (HSLGKWLGHPDKF) en-
compasses aa residues 139–151 of PLP and is encephalitogenic
in SJL/J mice (26). MOG peptide (MEVGWYRSPFSRVVH-
LYRNGK), encompassing aa residues 35–55 of MOG, is en-
cephalitogenic in C57Bl/6 mice (23).
 
CNS Homogenate.
 
50 frozen unstripped rat brains (Pelfreez
Biologicals) were homogenized in PBS using a Waring blender
and adjusted to 300 mg/ml with PBS.
 
Ig-Chimeras.
 
The Ig-PLP1 chimera harbors PLP1 peptide
within the heavy chain CDR3 region and has been described
previously (20–22). The Ig-MOG chimera harbors MOG 35–55
peptide within the heavy chain CDR3 region and, like Ig-PLP1,
was constructed using the genes coding for the IgG2b, 
 
 
 
 anti-
arsonate antibody, 91A3 as described previously (20). In brief, the
D segment was deleted from the CDR3 of the 91A3 heavy chain
variable region and replaced with a nucleotide sequence that
code for MOG35–55 peptide using mutagenesis procedures sim-
ilar to those described for the generation of Ig-PLP1 (20). The
resulting 91A3-MOG chimeric IgG2b heavy chain was cotrans-
fected with the parental 91A3 
 
 
 
 chain into the non-Ig–produc-
ing SP2/0 myeloma B cell line, and the transfectoma cells pro-
ducing complete Ig-MOG were selected with drugs as described
previously (20). Transfection, cloning, sequencing, and purifica-
tion procedures for Ig-MOG are similar to those used for Ig-
PLP1 (20).
The chimeras were agg by precipitation with 50%-saturated
(NH
 
4
 
)
 
2
 
SO
 
4
 
 as has been described previously (21, 22). Since both
Ig-PLP1 and Ig-MOG derive from the same Ig backbone and
thereby comprise identical IgG2b isotype, their Fc-associated
functions including binding and cross-linking of Fc
 
 
 
R will be
similar. In this respect we may refer to them indistinguishably as
Ig chimeras.
 
Isolation of DCs
 
Splenic DCs were purified according to the standard collage-
nase/differential adherence method (27). In brief, the spleen was
disrupted in a collagenase solution, and isolated DCs floated on a
dense BSA gradient. Subsequently, the cells were allowed to ad-
here to Petri dishes for 90 min at 37
 
 
 
C, washed, and incubated
overnight. For isolation of DC subsets, the bulk DCs were incu-
bated with anti-CD8
 
 
 
 mAb coupled microbeads (Miltenyi Bio-
tec) and separated into CD8
 
 
 
 
 
 and CD8
 
 
 
  
 
populations by
MACS
 
®
 
 (Miltenyi Biotec). The CD8
 
 
 
  
 
fraction was repassed on
magnetic columns after incubation with anti-CD8
 
 
 
 
 
 mAb cou-
pled microbeads to eliminate any residual CD8
 
 
 
 
 
 cells. Subse-
quently, the CD8
 
 
 
  
 
cells were further purified by positive selec-
tion using anti-CD11c mAb coupled microbeads (Miltenyi
Biotec). For preparation of CD8
 
 
 
 
 
CD4
 
 
 
 and CD8
 
 
 
 
 
CD4
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subsets, the CD8
 
 
 
  
 
fraction was labeled with anti-CD4 mAb
coupled microbeads (Miltenyi Biotec), and the subsets were sepa-
rated as above. The CD4
 
  
 
fraction was further purified by posi-
tive selection using anti-CD11c mAb coupled microbeads (Mil-
tenyi Biotec). Each fraction was assessed for purity and no
population was used if contamination was 
 
 
 
5%.
 
Induction of EAE
 
6–8-wk-old mice were induced for EAE by subcutaneous in-
jection in the footpads and at the base of the limbs and tail with a
200 
 
 
 
l IFA/PBS (vol/vol) solution containing 6 mg CNS ho-
mogenate and 200 
 
 
 
g 
 
Mycobacterium tuberculosis
 
 H37Ra (Difco
Laboratories). 6 h later the mice were given intravenous 200 ng
of purified 
 
Bordetella pertussis
 
 toxin (List Biological Laboratories,
Inc.). A second injection of 
 
B. pertussis
 
 toxin was given after 48 h.
Subsequently, the mice were scored daily for clinical signs of EAE
as follows: 0, no clinical score; 1, loss of tail tone; 2, hind limb
weakness; 3, hind limb paralysis; 4, forelimb paralysis; and 5,
moribund or death. EAE induced by CNS homogenate manifests
as a monophasic disease in C57Bl/6 mice and as a relapsing/re-
mitting disease in SJL/J mice. For induction of EAE with pep-
tide-pulsed DCs, the following procedure was used: purified
CD8
 
 
 
 
 
 or CD8
 
 
 
  
 
DCs (10
 
6
 
 cells/ml) were pulsed overnight
with 50 
 
 g/ml PLP1 peptide, washed, resuspended in PBS, and
injected subcutaneously into the hind limb footpads of mice at
3   105 cells per mouse. 6 and 24 h later, the mice were given
intravenously 200 ng of B. pertussis toxin.
Treatment of EAE
Treatment with Peptide. Mice induced for EAE with CNS ho-
mogenate began receiving treatment with 100  g of PLP1 or
MOG peptide after loss of tail tone, which occurs regularly be-
tween days 6 and 8 after disease induction. Treatment injections
were given intraperitoneally in PBS on days 9, 13, and 17 as de-
scribed previously (21).
Treatment with Ig-PLP1 or Ig-MOG. Mice induced for EAE
with CNS homogenate began receiving treatment with 300  g
of agg Ig-PLP1 or Ig-MOG after loss of tail tone. Treatment
injections were given intraperitoneally in PBS on days 9, 13,
and 17 after disease induction as described previously (21).
Treatment of EAE in Fc R /  mice reconstituted with wild-
type DCs was performed as follows: on day 5 after disease in-
duction, the mice were adoptively transferred intraperitoneal
with either 0.3 or 0.6   106 purified DCs. Subsequently, the
animals were treated with agg Ig-MOG on days 9, 13, and 17
as above.
Cytokine Detection
ELISA. ELISA was performed according to BD PharMin-
gen’s standard protocol. The capture Abs were as follows: rat
anti–mouse IFN- , R4–6A2; rat anti–mouse IL-10, JES5–2A5;
rat anti–mouse IL-4, 11B11; and rat anti–mouse IL-12, 9A5. The
biotinylated anti-cytokine Abs were as follows: rat anti–mouse
IFN- , XMG1.2; rat anti–mouse IL-10, JES5–16E3; rat anti–
mouse IL-4, BVD6–24G2; and rat anti–mouse IL-12, C17.8. All
antibodies were purchased from BD PharMingen. Assays were
read on a SPECTRAmax 190 counter (Molecular Devices).
Graded amounts of recombinant mouse IL-4, IFN-  (BD
PharMingen), IL-10, or IL-12 (Peprotech) were included in all
experiments for construction of standard curves. The cytokine
concentration in culture supernatants was interpolated from the
linear portion of the standard curve.
Intracellular Cytokine Staining. CD8  , CD8  CD4 , or
CD8  CD4  DCs (106 cells/ml/well) were incubated with 0.6
 M agg Ig-chimera for 24 h to allow for Fc R cross-linking.
During the last 8 h of incubation, brefeldin A (10  g) (Epicentre
Technologies) was added to the wells in order to block cytokine
secretion. The cells were then harvested and stained with anti-
CD11c-APC mAb, HL3, and FITC-labeled anti-CD8  mAb,
53–6.7, or anti-CD4 mAb, GK1.5. Subsequently, the cells were
fixed, permeabilized with 0.5% saponin (Sigma-Aldrich), and
stained for intracellular IL-10 using PE-labeled anti–IL-10 mAb,
JES5–16E3. The FACS® data were analyzed on a FACSVan-
tage™ Flow Cytometer (Becton Dickinson) using CELLQuest™
software (Becton Dickinson).
Stimulation of Cytokine Production by APCs
Splenocytes and subsets of DCs from normal or Fc R-defi-
cient mice were plated with graded amounts of soluble (sol) or
agg Ig-PLP1, and the culture was then incubated for 24 h. Detec-
tion and quantification of cytokines was then assessed by ELISA
from 100  l of culture supernatant as described above.
T Cells
TCC-PLP1–1B10. The generation of the PLP1-specific
Th0 cell clone, TCC-PLP1–1B10, has been described previously
(21). In brief, SJL mice were immunized with 100  g PLP1 pep-
tide in CFA, and 10 d later the draining lymph nodes were re-
moved and stimulated with PLP1. After three stimulation/resting
cycles, the cells were cloned twice by limiting dilution, and posi-
tive clones were retested for reactivity with PLP1 peptide by both
proliferation and cytokine production. Subsequently, one positive
clone displaying a Th0 pattern was selected and designated TCC-
PLP1–1B10.
MOG-specific T Cell Line. A similar procedure was used to
generate a MOG reactive T cell line and these cells were used for
testing Ig-MOG for peptide presentation.
Analysis of Cytokine Responses Upon Presentation of agg
Ig-PLP1 by Subsets of DCs
Purified bulk, CD8  , or CD8   DCs were plated at 5   104
cells/well/50  l and incubated with graded amounts of sol or agg
Ig-PLP1 (100  l/well) for 1 h. Subsequently, TCC-PLP1–1B10
cells (5   104 cells per well per 50  l) were added, and the cul-
ture was continued for 24 h. Detection and quantification of cy-
tokines were assessed by ELISA from 100  l of culture superna-
tant as described above.
Results
Broad Efficacy of agg Ig-myelin Chimeras in the Suppression of
EAE. We have previously demonstrated that agg Ig-
PLP1 is effective in the induction of IL-10 by APC and
modulation of EAE involving diverse T cell specificities
(21, 22). Furthermore this study indicated that IL-10–
mediated bystander suppression plays a critical role in T cell
modulation and amelioration of EAE, as administration of
anti–IL-10 mAb into mice during treatment of disease with
agg Ig-PLP1 restored full severity of paralysis (21, 22). This
experimental model of T cell tolerance was used in con-
junction with Fc R-deficient mice to devise an adoptive
APC transfer system suitable for evaluation of the role of
DCs in peripheral tolerance. Since Fc R-deficient mice220 CD8  CD4  Dendritic Cells in Peripheral Tolerance
were not available in the H-2s (SJL/J) background we in-
stead chose to use C57Bl/6 (H-2b) mice and therefore
engineered an Ig-MOG chimera containing the I-Ab–
restricted MOG35–55 peptide, an epitope that has been
shown to induce EAE in C57Bl/6 mice (23). To ensure
that the MOG peptide would indeed be processed from
the chimera and presented to specific T cells, Ig-MOG was
assayed for stimulation of a T cell line generated against
MOG35–55 peptide. The results showed that the MOG-
specific T cell line significantly proliferated when it was in-
cubated with Ig-MOG in the presence of compatible APC,
thus indicating that Ig-MOG was taken up by the APC and
that a MOG peptide was generated and presented to the T
cells (unpublished data).
Subsequently, Ig-MOG was tested for amelioration of
EAE in C57Bl/6 mice side by side with Ig-PLP1 in the SJL
strain. The results indicate that agg Ig-MOG, like agg Ig-
PLP1, was able to reverse CNS homogenate induced EAE
and, most likely, involved downregulation of diverse T cell
specificities (Fig. 1). Indeed, while the untreated C57Bl/6
mice had a mean maximal score of 2.4   0.2, those treated
with agg Ig-MOG had a mean maximal score of 1.2   0.3
(Fig. 1 B). In addition, while agg Ig-MOG treated animals
fully recovered from the typical monophasic EAE by day
22 after disease induction, the recovery of the untreated
mice was delayed and occurred on day 47. This concurs
with the SJL/Ig-PLP1 system in which the untreated mice
had a mean maximal disease score of 2.8   0.3 and had not
recovered by day 60 post disease induction, as relapses were
still observed. Those treated with agg Ig-PLP1 had a mean
maximal disease score of 1.4   0.3 and fully recovered
from this relapsing/remitting disease by day 26 after induc-
tion, and relapses were not observed (Fig. 1 A). Further-
more, free PLP1 and MOG peptides used at 17- and 19-fold
excess, respectively, were unable to suppress the clinical
signs of EAE in their respective mouse strains (Fig. 1).
These results indicate that the agg Ig chimeras display a
broad effectiveness in reversing disease involving multiple
epitopes and, most likely, diverse T cell specificities.
DCs Mediate the Reversal of EAE by agg Ig-myelin Chime-
ras. In prior studies, we demonstrated that DCs produce
IL-10 upon cross-linking of their Fc R by agg Ig-PLP1
(21). Since neutralization of IL-10 during treatment of dis-
eased mice with agg Ig-PLP1 restored clinical severity, it is
possible that DCs play a critical role in the suppression of
EAE (21). To evaluate the contribution of DCs to this
form of peripheral T cell tolerance, an animal model where
both antigen presentation and IL-10 secretion are compro-
mised was needed. Since our delivery molecule belongs to
the IgG2b subclass, an isotype that internalizes into APC
via Fc R (20, 28) and induces IL-10 by the cross-linking
of these receptors (21, 22), mice deficient in Fc R expres-
sion would provide such a model. The Fc R family is di-
vided into three subfamilies that either employ an  -chain
that mediates both Ig binding and signaling (Fc RII) or an
 -chain that mediates Ig binding and a  -chain responsible
for signaling (Fc RI and III) (for a review, see reference
29). Mice in which the  -chain of Fc RII was knocked
out generated animals that were deficient for Fc RII
(Fc RII / ) but displayed intact Fc RI and III (24). Also,
gene targeted mutation of the common  -chain generated
mice that were deficient in Fc RI and III (Fc RI and III / ),
Figure 1. Agg Ig-MOG modulates disease involving diverse T cell
specificities. Groups of SJL/J (A) or C57Bl/6 (B) mice were induced for
EAE with 6 mg of CNS homogenate and were treated intraperitoneally
with a saline solution containing 300  g of agg Ig-PLP1 (agg Ig-PLP1),
300  g agg Ig-MOG (agg Ig-MOG), 100  g of free PLP1 peptide (PLP1
peptide), or 100  g MOG peptide (MOG peptide) on days 9, 13, and 17
after disease induction. On the basis of the molecular weight of the Ig-
chimeras and PLP1 and MOG peptide, we estimated that 300  g of free
peptide contains 17- and 19-fold higher copies of peptide, respectively,
than the Ig-chimera. Groups of untreated mice (Nil) were included for
comparison purposes. The clinical onset of disease was at day 5–7 after
disease induction in these experimental groups. Each point represents the
mean clinical score of six mice.
Figure 2. The induction of IL-10 production by agg Ig-chimeras is
mediated primarily by Fc RI. Splenocytes from C57Bl/6 (A); Fc RII / 
(B); Fc RI, III /  (C); and Fc RI, II, and III /  (D) mice were incu-
bated with graded amounts of agg (white circles) or sol (black circles) Ig-
MOG for 24 h. Subsequently, the supernatant was used to measure IL-10
production by ELISA. To determine the contribution of Fc RI and Fc-
 RIII in mediating IL-10 production, the following experiment was per-
formed (insert to B): DCs from Fc RII /  mice were incubated with 0.6
 M of agg Ig-chimera in the presence of 20  g/ml 2.4G2 mAb (hatched
bar) or 100  g/ml mouse IgG (white bar), and IL-10 production was
evaluated. Each point represents the mean of triplicate wells. The dotted
line indicates the lower limit of cytokine detection in this ELISA.221 Legge et al.
but not Fc RII expression (25). Genetic crossing of these
two mutant strains generated mice deficient for all three
types of Fc Rs (Fc RI, II, and III / ) (25). Using these
mutant mice, we identified Fc RI as the major mediator of
agg Ig-chimera induced IL-10 production by APCs (Fig.
2). Indeed, splenocytes from C57Bl/6 or Fc RII /  mice
produced IL-10 upon incubation with agg Ig-MOG (Fig.
2, A and B), while those from Fc RI and III /  or Fc RI,
II, and III /  mice did not, as IL-10 production remained
at the background level seen with the negative control, sol
Ig-MOG (Fig. 2, C and D). Similar results were obtained
when DCs were used instead of splenocytes (unpublished
data). These results indicated that Fc RI and/or Fc RIII
was responsible for binding agg Ig-MOG and triggering
the IL-10 production by the APC. However, blockade of
Fc RIII with 2.4G2 antibody, which is specific for both
Fc RII and III (30), on cells lacking Fc RII still allowed
for equivalent IL-10 production indicating that Fc RI is
most likely the major binder and, thus, mediator of agg Ig-
MOG induced IL-10 production (Fig. 2, B insert). There-
fore, Fc RI and III /  mice provide an appropriate model
for the adoptive transfer of wild-type C57Bl/6 APC in or-
der to investigate the role of DCs in the suppression and
reversal of EAE by agg Ig-chimeras. Accordingly, Fc RI
and III /  mice that had been induced for EAE with CNS
homogenate were given C57Bl/6 DCs on day 5 after dis-
ease induction and were treated with agg Ig-MOG when
EAE had became clinically apparent. As can be seen in Fig.
3, the Fc RI and III /  mice developed a severe disease
(2.6   0.2) in response to CNS homogenate (no transfer/
no treatment group). In contrast to the wild-type C57Bl/6
mice, these Fc RI and III /  mice could not reverse their
disease upon similar treatment with the agg Ig-MOG (no
transfer/agg Ig-MOG group). However, if these mice were
reconstituted with wild-type DCs from C57Bl/6 mice be-
fore treatment with agg Ig-MOG, the severity of EAE was
significantly reduced (mean maximal score of 1.1   0.2),
and the animals recovered by day 20 after disease induction
(DC transfer/agg Ig-MOG group). Adoptive transfer of
DCs without treatment with agg Ig-MOG had a marginal
effect on disease manifestation (DC transfer/no treatment
group). These results indicate that DCs play a critical role
in this form of peripheral tolerance and suppression of au-
toimmunity.
We have previously shown that modulation of disease
by the Ig-chimeras is due to tolerization of myelin-specific
T cells and suppression of their proliferation as well as
IFN-  production (21). In addition, the IL-10 produced
by APC, upon binding of agg Ig-myelin chimeras was
Figure 3. DCs mediate reversal of EAE by agg Ig-chimeras. Groups of
Fc RI and III /  mice (6–8 wk of age) were induced for EAE with 6 mg
of CNS homogenate, and on day 5 after disease induction, adoptively
transferred with 0.6   106 purified C57Bl/6 DCs (squares). Subsequently,
the mice were treated intraperitoneally with 300  g agg Ig-MOG on days
9, 13, and 17 after disease induction (white symbols). Groups of untreated
mice that either received (black squares) or did not receive (black circles)
DC transfer and mice that were treated with agg Ig-MOG but did not re-
ceive DC transfer (white circles) were included for comparison purposes.
The clinical onset of disease was at day 5 in these experimental groups.
Each point represents the mean clinical score of 6–8 mice.
Figure 4. DCs produce IL-10 and downregulate IL-12
upon incubation with agg Ig-PLP1. 20,000 purified DCs
(A) were incubated with graded amounts of agg Ig-PLP1
for 24 h, and the supernatant was then used to measure
both IL-10 and IL-12 production by ELISA. In the right
panel the stimulation with agg Ig-PLP1 was performed in
the presence of 20  g/ml anti–mouse IL-10 mAb anti-
body (2A5) or negative control rat IgG. Subsequently IL-10
(B) and IL-12 (C) were measured by ELISA. Each point
or bar represents the mean of triplicate wells. The dotted
line indicates the lower limit of cytokine detection in
this ELISA.222 CD8  CD4  Dendritic Cells in Peripheral Tolerance
shown to play a critical role in T cell tolerization, as its
neutralization by administration of anti–IL-10 antibodies
restored disease severity (21). Suppression of EAE by agg
Ig-myelin chimeras could operate through the direct bind-
ing of IL-10 to the autoreactive T cells leading to inhibi-
tion of their proliferation (31–33). Alternatively, IL-10
may downregulate IL-12 production by the APC and lead
to defective T cell differentiation (31, 34, 35). To test this
premise, we assayed DCs for production of IL-12 upon in-
cubation with agg Ig-MOG and assessed whether any such
IL-12 secretion would be subject to downregulation by
IL-10. As can be seen in Fig. 4, DCs produced both IL-10
and IL-12 upon incubation with agg Ig-MOG. However,
the secretion of IL-12 decreased as IL-10 production in-
creased suggesting a regulation of IL-12 by IL-10. In fact
the addition of an anti–IL-10 mAb to the culture to neu-
tralize IL-10 supported this view and allowed for IL-12 se-
cretion at higher concentrations of agg Ig-chimera (Fig. 4,
B and C).
The CD8  , but not CD8  , DC Population Is Responsi-
ble for IL-10 Production and Reversal of EAE upon Treatment
with agg Ig-MOG. While all DCs defined to date function
as APC, they are quite heterogeneous in their surface phe-
notypes (36, 37). Recently, it has become clear that the dif-
ferent DC subtypes display different trafficking patterns
(38) and contribute distinct developmental functions in T
cell priming (7, 8). Since DCs produce IL-10 and mediate
reversal of EAE upon treatment with agg Ig-MOG, this
model offers an opportunity to investigate the role of the
DC subsets in peripheral T cell tolerance. Initially, DCs
were separated into CD8   and CD8   populations and
tested for both IL-10 and IL-12 production upon incuba-
tion with agg Ig-MOG. As illustrated in Fig. 5, CD8  
DCs produced IL-10, while CD8   DC secreted IL-12,
upon cross-linking of their Fc Rs by agg Ig-PLP1. The
production of IL-12 by CD8   DCs was also inducible by
sol Ig-PLP1, possibly indicating that binding of monomeric
IgG to Fc Rs is sufficient to trigger IL-12 secretion. Alter-
natively, some sol Ig-PLP1 might have agg during culture
at 37 C. If this is the case, IL-12 induction requires only a
small amount of agg Ig relative to that required for the in-
duction of IL-10 (Fig. 4).
Since the CD8   DCs produced IL-10 upon incubation
with agg Ig-PLP1, T cells engaged by these APCs through
peptide presentation should be tolerized rather than stimu-
lated (31, 32). To test this premise, the PLP1-specific Th0
clone, TCC-PLP1–1B10 (21), was incubated with CD8  
DCs in the presence of sol or agg Ig-PLP1 and both IL-10
production by the APC and IFN-  secretion by the T cells
were measured. For comparison purposes, bulk and CD8  
DCs were included in these experiments. As can be seen in
Fig. 6, A and B, CD8   DCs, which do not produce IL-10
upon incubation with agg or sol Ig-PLP1, activated the
Th0 clone to produce IFN-  through presentation of
PLP1 peptide. In contrast, CD8   DCs, which produce
IL-10 upon incubation with agg Ig-PLP1 (Fig. 6 C), were
not able to drive production of IFN-  by the Th0 clone
(Fig. 6 D). Surprisingly, incubation with sol Ig-PLP1,
Figure 5. CD8   DCs produce IL-10, while CD8   DCs secrete IL-12
in response to agg Ig-PLP1. 50,000 purified CD8   (A and C) or
CD8   (B and D) DCs were incubated with graded amounts of agg
(white circles) or sol (black circles) Ig-PLP1 for 24 h. Subsequently, the
supernatant was used to measure both IL-10 (A and B) and IL-12 (C and
D) production by ELISA. Each point represents the mean of triplicate
wells. The results shown are representative of four experiments. The
dotted line indicates the lower limit of cytokine detection in this ELISA.
Figure 6. CD8   DCs are unable to promote the production of IFN- 
by T cells. Purified CD8   (A and B), CD8   (C and D), and unsepa-
rated CD11c  (E and F) DC (5   104 cells per well) were incubated with
graded amounts of agg (black circles) or sol (white circles) Ig-PLP1 for
1 h. Subsequently, TCC-PLP1–1B10 Th0 cells (5   104 cells per well)
were added, and the incubation was continued for 24 h. IL-10 (A, C, and
E) and IFN-  (B, D, and F) production in the same culture well were
then measured by ELISA from 100  l of culture supernatant. The insert
in D, measuring IL-4 secretion, indicates that the absence of IFN-  pro-
duction by the T cells upon stimulation with CD8   DCs and Ig-PLP1
was not due to inadequate antigen presentation. Each point represents the
mean of triplicate wells. The dotted line indicates the lower limit of cy-
tokine detection in this ELISA.223 Legge et al.
which does not cross-link Fc R or trigger IL-10 produc-
tion by the CD8   DCs (Fig. 6 C), was unable to stimulate
the Th0 clone for IFN-  production (Fig. 6 D). The lack
of IFN-  was not due to defective presentation of sol Ig-
PLP1 as the Th0 clone was able to produce IL-4 in re-
sponse to such stimulation (Fig. 6, D insert). Nevertheless,
the IL-10 produced by the CD8   subset within the bulk
DC population (Fig. 6 E) suppressed the capacity of the
CD8   subset to drive IFN-  production by the T cells
(Fig. 6 F), a phenomenon that further argues for the tolero-
genic function of CD8   DCs. Overall, the results of this
in vitro experiment with a Th0 clone demonstrate that
CD8   DCs do not support the polarization of T cells into
IFN- –producing cells and can actively antagonize the ac-
tivation of Th1 cells through IL-10 production.
The ability of CD8   DCs to mediate T cell tolerance
in vivo was then analyzed. To this end, CD8   DCs were
adoptively transferred into Fc RI and III /  mice and
tested for reversal of EAE upon treatment with agg Ig-
MOG. The results illustrated in Fig. 7 indicate that transfer
of either 3 or 6   105 C57Bl/6 CD8   DCs into Fc RI
and III /  mice with ongoing clinical EAE allowed for the
reversal of paralysis when the mice were treated with agg
Ig-MOG. However, mice adoptively transferred with
CD8   DCs, instead of the CD8   population, were un-
able to suppress the disease and had clinical scores similar to
mice that did not receive any cell transfer. These results in-
dicate that CD8   DCs are responsible for tolerization of
pathogenic myelin-specific Th1 T cells and, thus, play a
critical role in this form of peripheral tolerance.
It has been previously shown that DCs loaded with anti-
genic peptide induce immune responses without the re-
quirement for adjuvant (3). This regimen provided a useful
approach to test the intrinsic tolerogenic function of the
CD8   DCs. Accordingly, CD8   and CD8   DCs were
loaded with an excess of PLP1 peptide in vitro and injected
into mice according to a regimen defined to induce EAE
(39). Daily analysis of paralytic scores indicated that
CD8  , but not CD8   DCs, induced EAE (Fig. 8).
Again, these results argue that PLP1-reactive T cells were
available but were unresponsive to PLP1 peptide when it
was presented by these CD8   DCs as activation and dif-
ferentiation into Th1 effectors that cause disease did not
occur (7, 8).
CD8  CD4 , but not CD8  CD4 , DCs Produce IL-
10 and Mediate Reversal of EAE upon Treatment with Ig-
MOG. The CD8   subset of splenic DCs is comprised of
two phenotypically different populations based upon the
expression of CD4 (37). However, whether these subsets,
CD8  CD4  and CD8  CD4 , display distinct biologic
functions has not yet been clarified. Herein, the two subsets
were separated from splenic DCs and tested for IL-10 pro-
duction as well as reversal of EAE upon treatment with agg
Ig-MOG. The results illustrated in Fig. 9 indicate that
CD8  CD4 , but not CD8  CD4  DCs, produce IL-10
upon incubation with agg Ig-MOG as tested by intracellu-
lar cytokine staining (Fig. 9, A and B). IL-10 production
was not observed with the CD8   subset that was used as a
negative control (Fig. 9 C). Subsequently, the two subsets
were adoptively transferred into Fc RI and III /  mice
with ongoing clinical EAE and tested for reversal of paraly-
sis upon treatment with agg Ig-MOG. The results indi-
cated that CD8  CD4 , but not CD8  CD4 , DCs
were able to mediate tolerance and reverse the disease upon
treatment with agg Ig-MOG (Fig. 9, D and E). Indeed, the
mice transferred with 3 or 6   105 CD8  CD4  DCs had
a mean maximal disease severity of 0.9   0.3 and fully re-
covered by day 18 after disease induction. Those trans-
ferred with equivalent numbers of CD8  CD4  DCs had
a mean maximal disease severity of 2.6   0.3 and did not
recover from their paralysis during the 21-d period of clin-
ical assessment. The reversal of EAE requires treatment
with agg Ig-MOG because adoptive transfer of 6   105
Figure 7. CD8   wild-type DCs restore agg Ig-MOG mediated rever-
sal of EAE in Fc RI and III /  mice. Groups of Fc RI and III /  mice
(6–8 wk of age) were induced for EAE with 6 mg of CNS homogenate.
On day 5 after disease induction, the mice were given intraperitoneally
3   105 (A) or 6   105 (B) purified C57Bl/6 CD8   (black circles) or
CD8   DCs (white circles). Subsequently, the mice were treated intra-
peritoneal with 300  g agg Ig-MOG on days 9, 13, and 17 after disease
induction. A group of mice that were treated with agg Ig-MOG but did
not receive cell transfer (white triangles) was included for comparison
purposes. The clinical onset of disease was at day 5 in these experimental
groups. Each point represents the mean clinical score of 6–8 mice.
Figure 8. CD8  , but not
CD8  , DCs promote the de-
velopment of EAE. Purified
CD8   (black circles) or
CD8   (white triangles) DCs
were pulsed overnight with 50
 g/ml PLP1 peptide, washed,
resuspended in PBS, and injected
(3    105 cells per mouse) into
the hind limb footpads of SJL/J
mice. 6 and 24 h later, the mice
were given intravenous 200 ng
of B. pertussis toxin. The clinical
onset of disease was at day 6 in
these experimental groups, and
each point represents the mean
clinical score of five mice.224 CD8  CD4  Dendritic Cells in Peripheral Tolerance
CD8  CD4  DCs did not confer reduction of the severity
of disease or recovery from paralysis when the animal were
not given agg Ig-MOG. These results identify the CD8  
CD4  DC subset as the tolerogenic population among ma-
ture splenic DCs.
Discussion
The results presented in this report show that C57Bl/6
mice recover from EAE when treated with agg Ig-MOG
as did SJL/J mice after treatment with agg Ig-PLP1 (Fig.
1). However, C57Bl/6 mice deficient for Fc RI and III
could not resolve EAE upon similar treatment with agg Ig-
MOG unless reconstituted with DCs from wild-type
C57Bl/6 mice before the treatment (Fig. 3). Previously,
we have shown that APC internalize Ig-chimera of the
same IgG2b backbone as Ig-MOG and Ig-PLP1 mainly via
Fc Rs leading to processing of the chimeras within endo-
somes and efficient loading of the incorporated peptide
onto newly synthesized MHC molecules (40). Aggrega-
tion of the Ig-chimeras adds another feature to the Ig de-
livery system, namely the cross-linking of Fc R and pro-
duction of IL-10 by the APC (21, 22). Fc RI was
identified as the main target for Ig-MOG and mice lacking
such a receptor could not resolve EAE (Fig. 3) most likely
due to compromised presentation of Ig-MOG and lack of
IL-10 production (Fig. 2). Furthermore, this report shows
that DCs produce IL-12 upon cross-linking of their Fc R
but that the simultaneous production of IL-10 negatively
regulates such IL-12 secretion (Fig. 4). This observation
prompted us to determine whether the two cytokines
were produced by the same or by separate subsets of DCs
and whether there was a correlation between a specific
population of DCs and recovery from disease. The find-
ings indicated that the IL-10 production was mediated by
CD8   DCs and IL-12 by the CD8   population (Fig. 5).
While this result is in good agreement with data obtained
recently with pansorbin (killed S. aureus) stimulated DCs
(41), it is also supported by the observation that CD8  
but not CD8   DCs mediate recovery from EAE in the
Fc RI and III /  mice upon treatment with Ig-MOG
(Fig. 7). Although different subsets of DCs may display dif-
ferent pattern of trafficking (38) and migration issues could
be at play in this form of peripheral tolerance, a number of
observations argue instead that these results represent in-
trinsic functions of the two populations. Fig. 6 shows that
upon incubation with agg Ig-PLP1 the CD8   DCs pro-
duce IL-12, present the PLP1 peptide, and stimulate the
PLP1-specific Th0 cells to produce IFN- . Therefore,
these cells most likely would not support reversal of EAE
upon encounter with pathogenic T cells when properly
located. However, CD8   DCs produced IL-10, did not
stimulate IFN-  production by the same Th0 cells (Fig. 6),
and therefore not surprisingly supported the reversal of
EAE (Fig. 7). Thus, in this in vitro T cell regulation sys-
tem, where migration issues should not be at play, the DC
subsets displayed functions that parallel the results obtained
in vivo. Furthermore, when the two subpopulations were
loaded with free peptide in vitro and then used to induce
EAE, only the CD8   DCs produced paralysis. This ob-
servation suggests that both naive self-reactive T cells were
available and that CD8   DCs were able to encounter
these cells and drive their activation and induction of pa-
ralysis. However, the CD8   DCs population seems to
mediate unresponsiveness as they did not activate the T
cells to produce EAE despite their ability to migrate
through the circulation, encounter the T cells and mediate
reversal of EAE as shown in Fig. 7. Thus, the intrinsic
function of these cells most likely dictates the type of con-
tribution that a DC subset displays in this model of periph-
eral tolerance. However, we cannot currently rule out that
differential trafficking patterns between the two popula-
tions influence their functions.
In recent years reports have been made indicating that
human immature DCs cross-presenting viral (42) or alloge-
neic (43) antigens induce IL-10–producing regulatory T
cells that could potentially sustain peripheral tolerance. In
addition, immature DCs were found to internalize apop-
totic bodies generated from normal cells dying as a conse-
quence of physiologic turnover, and transport the associ-
ated self-antigens to nearby lymph nodes populated with T
Figure 9. CD8  CD4  DCs produce IL-10 and mediate reversal of
EAE. IL-10 production by purified (A) CD11c CD8  CD4 , (B)
CD11c CD8  CD4 , and (C) CD11c CD8   DCs was measured by
intracellular cytokine staining. Accordingly, DCs (106 cells per well) were
incubated with 0.6  M agg Ig-PLP1 for 24 h and brefeldin A (10  g) was
added to the wells during the last 8 h of incubation, in order to block cy-
tokine secretion. Subsequently, the cells were harvested and stained with
anti–CD11c-APC and FITC-labeled anti-CD8  or anti-CD4 mAb. The
cells were then fixed, permeabilized, and intracellular stained with PE-
conjugated anti–IL-10 (thick lines) or isotype matched (dotted lines) mAb.
Cells incubated with media without the addition of Ig-PLP1 (thin lines)
and intracellular stained with anti–IL-10-PE mAb were included for con-
trol purposes. Shown are histogram plots representing the intensity of
IL-10 expression by the indicated DC population. The results shown are
representative of four experiments. In D and E, groups of Fc RI and
III /  mice (6–8 wk of age) were induced for EAE with 6 mg of CNS
homogenate and on day 5 the mice were given intraperitoneally 3   105
(D) or 6   105 (E) purified C57Bl/6 CD8  CD4  (black circles) or
CD8  CD4  (white circles) DCs. Subsequently, the mice were treated
intraperitoneal with 300  g agg Ig-MOG on days 9, 13, and 17 after dis-
ease induction. A group of untreated mice that received 0.6   106
CD8  CD4  DC (white triangles) was included for comparison pur-
poses. The clinical onset of disease was at day 5 in these experimental
groups. Each point represents the mean clinical score of 6–8 mice.225 Legge et al.
cells (10, 44). Since T cell responses to those self-antigens
were undetectable it was presumed that such transport
served to maintain peripheral T cell tolerance (19, 44). The
contribution of DCs to peripheral tolerance, however, re-
mains largely undefined. Lately, it has been shown that re-
petitive injections of TNF-  matured peptide-loaded DCs
can protect against EAE presumably via induction of IL-
10–producing regulatory T cells (45). Moreover, peptide
loading into the endosomal compartment of DCs in the ab-
sence of inflammation also supports T cell down-regulation
and likely maintains peripheral tolerance (46). The Ig-chi-
meras drive both peptide loading into endosomes without
causing inflammation, and induce IL-10 production by
APC aligning powerful factors against the self-reactive T
cells. Interestingly, among the mature splenic DCs, the
CD8   CD4  subset seems to drive such tolerance as they
produce IL-10 and support reversal of EAE in the Fc RI
and III /  mice (Fig. 9). Given the small size of the
CD8   CD4  DCs population we suspect that such po-
tency emanated from coordinated inhibitory functions. IL-
10 produced by the CD8   CD4  DCs could inhibit the
function of T cells (47) directly by alteration of CD28 ex-
pression (33), and/or indirectly by downregulation of IL-
12 from the CD8   DCs (Figs. 4 and 6). Furthermore, we
believe that the CD8   DCs and more specifically the
CD8  CD4  subpopulation display tolerizing effects on
Th1 cells as they were unable to drive IFN-  production
by the Th0 T cell clone even upon stimulation with sol Ig-
PLP1, a chimera which does not induce IL-10 production
(Fig. 6). The observation that CD8   DCs loaded with
free PLP1 peptide (hence no IL-10 involvement) were un-
able to induce EAE, while CD8   DCs did, (Fig. 8) fur-
ther supports the idea that CD8   DCs are tolerogenic
against Th1 cells.
CD8   DCs, which proved tolerogenic against Th1 re-
sponses in this model, have previously been shown to pro-
mote the development of Th2 cells (7, 8). Thus, the ques-
tion that arises is whether the same DCs display a functional
plasticity and prime Th2 responses while tolerizing for Th1
immunity, or if each function is confined to a distinct sub-
set within the CD8   population. The latter was con-
firmed for the tolerizing function as the CD8  CD4 , but
not the CD8  CD4 , subset was found to produce IL-10
and reverse EAE upon treatment with agg Ig-MOG (Fig.
9). Therefore, we believe the CD8  CD4  subset of ma-
ture splenic DCs displays intrinsic tolerizing properties
complemented with the ability to produce IL-10 and play a
critical role in peripheral tolerance against self-reactive T
cells. Whether or not these cells represent the described
previously (6, 19, 48) mature DC subset specialized in T
cell tolerance is not clear at this time.
Our prior studies of disease reversal using agg Ig-PLP1 in
the SJL system have not been able to detect regulatory T
cells (21). Since regulatory T cells usually adopt a cycling
pattern (49) and may be subject to self-limitation upon
modulation of the pathogenic T cells, they may be difficult
to detect subsequent to recovery from disease. If this is the
case the possibility remains that CD8  CD4  DCs are able
to induce regulatory T cells, particularly that they produce
IL-10, a growth factor for regulatory T cells (34). What-
ever the mechanism might be, these cells seem to be very
potent, as tolerance has occurred in two different antigenic
systems using two different mouse strains and the disease
was reversed even in SJL mice where the autoreactive T
cell repertoire encompasses an usual high frequency of self-
reactive T cells (50).
Overall, these investigations have identified a DC subset
that displays powerful modulatory effects on autoreactive T
cells and provides a DC candidate that could sustain pe-
ripheral tolerance against self-antigens.
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